We already require authorization today for our commercial and Medicare Advantage members for this service as part of medical policy 297: Transcranial Magnetic Stimulation as a Treatment of Depression and Other Psychiatric/Neurologic Disorders.
We’ve posted new, revised, clarified, and retired medical and pharmacy medical policies, effective in September 2024.
Medical policy 132, Medicare Advantage Management
(This document explains whether we use CMS criteria—or our own—to make coverage determinations for our Medicare Advantage members.)
Medicare Advantage section of our medical policy site.
Visit fepblue.org and search for medical policies.
MPC_110215-3D